Marinus Pharmaceuticals’ (MRNS) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Marinus Pharmaceuticals (NASDAQ:MRNSFree Report) in a research report sent to investors on Wednesday morning, Benzinga reports. They currently have a $27.00 price objective on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Marinus Pharmaceuticals’ Q1 2024 earnings at ($0.69) EPS, Q2 2024 earnings at ($0.59) EPS, Q3 2024 earnings at ($0.60) EPS, Q4 2024 earnings at ($0.49) EPS, FY2024 earnings at ($2.37) EPS, FY2025 earnings at ($1.61) EPS, FY2026 earnings at ($0.62) EPS, FY2027 earnings at $1.85 EPS and FY2028 earnings at $5.33 EPS.

Other research analysts also recently issued research reports about the company. Truist Financial lowered their price target on Marinus Pharmaceuticals from $32.00 to $25.00 and set a buy rating on the stock in a report on Wednesday, November 8th. StockNews.com upgraded Marinus Pharmaceuticals from a sell rating to a hold rating in a research note on Saturday, January 27th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of Moderate Buy and a consensus price target of $21.21.

Read Our Latest Report on MRNS

Marinus Pharmaceuticals Trading Up 1.1 %

Shares of MRNS stock opened at $8.85 on Wednesday. Marinus Pharmaceuticals has a 1-year low of $5.57 and a 1-year high of $11.26. The company has a current ratio of 4.07, a quick ratio of 6.29 and a debt-to-equity ratio of 5.68. The stock’s fifty day simple moving average is $9.95 and its 200-day simple moving average is $8.28.

Marinus Pharmaceuticals (NASDAQ:MRNSGet Free Report) last issued its quarterly earnings results on Tuesday, March 5th. The biopharmaceutical company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.10). Marinus Pharmaceuticals had a negative net margin of 456.31% and a negative return on equity of 269.75%. The business had revenue of $7.19 million for the quarter, compared to analysts’ expectations of $7.78 million. During the same quarter in the prior year, the firm posted ($0.76) EPS. On average, sell-side analysts expect that Marinus Pharmaceuticals will post -2.35 earnings per share for the current fiscal year.

Institutional Trading of Marinus Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in MRNS. MetLife Investment Management LLC lifted its position in shares of Marinus Pharmaceuticals by 63.8% in the first quarter. MetLife Investment Management LLC now owns 20,363 shares of the biopharmaceutical company’s stock worth $190,000 after buying an additional 7,928 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Marinus Pharmaceuticals by 2.5% in the first quarter. Charles Schwab Investment Management Inc. now owns 95,047 shares of the biopharmaceutical company’s stock worth $889,000 after buying an additional 2,281 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in shares of Marinus Pharmaceuticals in the first quarter worth about $317,000. Goldman Sachs Group Inc. lifted its position in shares of Marinus Pharmaceuticals by 3.5% in the first quarter. Goldman Sachs Group Inc. now owns 156,949 shares of the biopharmaceutical company’s stock worth $1,468,000 after buying an additional 5,380 shares during the last quarter. Finally, Quantbot Technologies LP acquired a new stake in shares of Marinus Pharmaceuticals in the first quarter worth about $40,000. Institutional investors and hedge funds own 88.26% of the company’s stock.

Marinus Pharmaceuticals Company Profile

(Get Free Report)

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.

See Also

Analyst Recommendations for Marinus Pharmaceuticals (NASDAQ:MRNS)

Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.